The Scientist

» IPO and developmental biology

Most Recent

image: Further Support for Early-Life Allergen Exposure

Further Support for Early-Life Allergen Exposure

By | September 20, 2016

Egg and peanut consumption during infancy is linked to lower risk of allergy to those foods later in life, according to a meta-analysis.

0 Comments

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

image: Another CRISPR Biotech Goes Public

Another CRISPR Biotech Goes Public

By | September 12, 2016

CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.

0 Comments

Disrupting the light/dark cycles of pregnant mice, researchers observe detrimental effects in the mouths of the animals’ pups.

0 Comments

image: Plastic Pollutants Can Harm Fish

Plastic Pollutants Can Harm Fish

By | June 6, 2016

European perch larvae exposed to environmentally relevant concentrations of polystyrene particles preferred to eat the microplastics in place of prey, according to a study.

0 Comments

image: Research at Micro- and Nanoscales

Research at Micro- and Nanoscales

By | June 1, 2016

From whole cells to genes, closer examination continues to surprise.  

1 Comment

image: Editing Genomes to Record Cellular Histories

Editing Genomes to Record Cellular Histories

By | May 26, 2016

Researchers harness the power of genome editing to track cell lineages throughout zebrafish development.

0 Comments

image: Embryo Watch

Embryo Watch

By | May 5, 2016

A new culture system allows researchers to track the development of human embryos in vitro for nearly two weeks. 

1 Comment

image: Cellular Pruning Follows Adult Neurogenesis

Cellular Pruning Follows Adult Neurogenesis

By | May 2, 2016

Newly formed neurons in the adult mouse brain oversprout and get cut back.

0 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise
RayBiotech